Modified CMV VLP–Feline IL-1β Conjugates for Aggregation Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing virus-like particle (VLP) based vaccines face challenges in stability, aggregation, and manufacturability, which are critical for clinical trial testing, product registration, and market launch, particularly due to the formation of aggregates under elevated temperatures and high ionic strengths.
Innovation Solution
The development of modified CMV VLPs with specific insertion of consecutive negative amino acids, such as glutamic acid and aspartic acid, to enhance stability and prevent aggregation, while linking feline Interleukin-1β muteins, resulting in CMV VLP-fIL-1β-D145X conjugates that maintain structural integrity and are suitable for scalable manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CMV VLPs are used with chemical linker coupling technology to present antigens, then immunogenicity is achieved, but stability and aggregation control deteriorate under elevated temperatures and high ionic strengths
Solution Approach 1:
The patent modifies the physical-chemical parameters of the VLP surface by introducing stretches of consecutive negative amino acids (glutamic acid and/or aspartic acid) at specific positions in the coat protein sequence. This parameter change alters the surface charge characteristics, creating electrostatic repulsion that prevents aggregation under elevated temperatures and high ionic strength conditions, thereby resolving the contradiction between maintaining immunogenicity and preventing aggregation.
Solution Approach 2:
The invention applies local modifications to specific regions of the CMV coat protein sequence (positions 75-85), rather than global modifications. By inserting negative amino acid stretches only at this specific location, the patent locally alters the surface properties to prevent aggregation while preserving the overall immunogenicity and structural integrity of the VLP antigen presentation capability.
2Reliability
If additional negative charges are inserted into VLP-forming proteins to improve stability, then aggregation is reduced, but VLP formation may be adversely affected
Solution Approach 1:
The patent carefully places negative amino acid stretches only at positions 75-85 of the coat protein sequence, a specific local region that does not interfere with the core VLP assembly mechanisms. This localized modification approach maintains proper VLP formation while conferring aggregation resistance, resolving the contradiction between improving stability and maintaining manufacturing precision.
Solution Approach 2:
The invention uses the native CMV coat protein sequence as a template and creates modified versions by inserting negative amino acid stretches at specific positions. This copying approach with controlled modifications allows the VLP to retain its natural assembly properties while gaining enhanced stability, preventing the adverse effects that might result from more extensive structural changes.
3Reliability
If VLP-based vaccines are developed for clinical trial testing and market launch, then immunogenicity is achieved, but manufacturability and scalability are limited due to aggregation issues
Solution Approach 1:
By modifying the amino acid sequence parameters of the coat protein to include negative stretches, the patent fundamentally changes the physical properties of the VLP to prevent aggregation. This parameter change enables reliable manufacturing and scaling up for clinical trials and market launch, as the modified VLPs remain stable under various processing conditions including elevated temperatures and high ionic strength buffers used in purification.
Solution Approach 2:
The patent converts the potential harm of charge modifications (which could disrupt VLP assembly) into a benefit by strategically placing negative amino acid stretches in a specific region that promotes electrostatic repulsion against aggregation. This transforms what could be a destabilizing modification into an aggregation-preventing feature that enhances manufacturability while preserving immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified CMV VLP-fIL-1β-D145X conjugates exhibit improved stability, prevent aggregation, and induce high titers of neutralizing antibodies, with reduced adverse effects, making them suitable for clinical use and commercial supply.
Implementation Method 1
insertion of stretches of consecutive negative amino acids, independently selected from aspartic acid and/or glutamic acid... lead to improvements in stability of the resulting modified CMV VLPs... under conditions of elevated temperatures and higher ionic strengths
Data Source
AI summary
The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which preferably comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which specific feline Interleukin-1β mutein antigens, fIL-1β-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against fIL-1β.